Annual Accounts Payable
$389.40 K
+$261.10 K+203.51%
30 April 2024
Summary:
PharmaCyte Biotech annual accounts payable is currently $389.40 thousand, with the most recent change of +$261.10 thousand (+203.51%) on 30 April 2024. During the last 3 years, it has risen by +$217.10 thousand (+126.00%). PMCB annual accounts payable is now -46.66% below its all-time high of $730.10 thousand, reached on 30 April 2012.PMCB Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$554.00 K
+$164.60 K+42.27%
31 July 2024
Summary:
PharmaCyte Biotech quarterly accounts payable is currently $554.00 thousand, with the most recent change of +$164.60 thousand (+42.27%) on 31 July 2024. Over the past year, it has increased by +$427.80 thousand (+338.99%). PMCB quarterly accounts payable is now -35.68% below its all-time high of $861.30 thousand, reached on 31 October 2022.PMCB Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PMCB Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +203.5% | +339.0% |
| 3 y3 years | +126.0% | +252.9% |
| 5 y5 years | +219.4% | +236.6% |
PMCB Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +203.5% | -35.7% | +496.3% |
| 5 y | 5 years | at high | +219.4% | -35.7% | +599.5% |
| alltime | all time | -46.7% | >+9999.0% | -35.7% | >+9999.0% |
PharmaCyte Biotech Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| July 2024 | - | $554.00 K(+42.3%) |
| Apr 2024 | $389.40 K(+203.5%) | $389.40 K(-19.6%) |
| Jan 2024 | - | $484.20 K(+283.7%) |
| Oct 2023 | - | $126.20 K(-82.4%) |
| July 2023 | - | $718.10 K(+459.7%) |
| Apr 2023 | $128.30 K(-37.5%) | $128.30 K(-71.2%) |
| Jan 2023 | - | $445.90 K(-48.2%) |
| Oct 2022 | - | $861.30 K(+54.1%) |
| July 2022 | - | $559.00 K(+172.2%) |
| Apr 2022 | $205.40 K(+19.2%) | $205.40 K(+121.1%) |
| Jan 2022 | - | $92.90 K(-40.8%) |
| Oct 2021 | - | $157.00 K(-60.2%) |
| July 2021 | - | $394.80 K(+129.1%) |
| Apr 2021 | $172.30 K(-7.3%) | $172.30 K(+117.6%) |
| Jan 2021 | - | $79.20 K(-1.1%) |
| Oct 2020 | - | $80.10 K(-79.2%) |
| July 2020 | - | $384.80 K(+107.1%) |
| Apr 2020 | $185.80 K(+52.4%) | $185.80 K(-45.4%) |
| Jan 2020 | - | $340.50 K(+106.9%) |
| Oct 2019 | - | $164.60 K(+143.9%) |
| July 2019 | - | $67.50 K(-44.6%) |
| Apr 2019 | $121.90 K(-65.4%) | $121.90 K(-8.8%) |
| Jan 2019 | - | $133.70 K(-61.6%) |
| Oct 2018 | - | $348.60 K(-39.4%) |
| July 2018 | - | $575.00 K(+63.1%) |
| Apr 2018 | $352.60 K(-3.6%) | $352.60 K(+15.4%) |
| Jan 2018 | - | $305.60 K(-1.7%) |
| Oct 2017 | - | $310.80 K(-50.5%) |
| July 2017 | - | $628.20 K(+71.8%) |
| Apr 2017 | $365.60 K(+8.8%) | $365.60 K(-16.0%) |
| Jan 2017 | - | $435.00 K(+44.6%) |
| Oct 2016 | - | $300.90 K(-3.4%) |
| July 2016 | - | $311.60 K(-7.3%) |
| Apr 2016 | $336.00 K(-32.4%) | $336.00 K(-51.8%) |
| Jan 2016 | - | $697.30 K(+63.2%) |
| Oct 2015 | - | $427.20 K(+3.4%) |
| July 2015 | - | $413.10 K(-16.8%) |
| Apr 2015 | $496.70 K(+164.2%) | $496.70 K(+32.2%) |
| Jan 2015 | - | $375.80 K(+38.1%) |
| Oct 2014 | - | $272.10 K(+33.1%) |
| July 2014 | - | $204.40 K(+8.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Apr 2014 | $188.00 K(-46.6%) | $188.00 K(+12.1%) |
| Jan 2014 | - | $167.70 K(-41.3%) |
| Oct 2013 | - | $285.70 K(-3.3%) |
| July 2013 | - | $295.60 K(-16.0%) |
| Apr 2013 | $352.00 K(-51.8%) | $352.00 K(-32.0%) |
| Jan 2013 | - | $517.40 K(+11.6%) |
| Oct 2012 | - | $463.70 K(+9.3%) |
| July 2012 | - | $424.20 K(-41.9%) |
| Apr 2012 | $730.10 K(+3.4%) | $730.10 K(+27.6%) |
| Jan 2012 | - | $572.30 K(-18.6%) |
| Oct 2011 | - | $703.00 K(+1.5%) |
| July 2011 | - | $692.60 K(-1.9%) |
| Apr 2011 | $705.80 K(+4.6%) | $705.80 K(-5.7%) |
| Jan 2011 | - | $748.70 K(+1.2%) |
| Oct 2010 | - | $739.90 K(+1.9%) |
| July 2010 | - | $726.10 K(+7.6%) |
| Apr 2010 | $674.80 K(+221.5%) | $674.80 K(+17.1%) |
| Jan 2010 | - | $576.50 K(+27.2%) |
| Oct 2009 | - | $453.40 K(+46.2%) |
| July 2009 | - | $310.20 K(+47.8%) |
| Apr 2009 | $209.90 K(+46.1%) | $209.90 K(+267.6%) |
| Jan 2009 | - | $57.10 K(+12.0%) |
| Oct 2008 | - | $51.00 K(+27.2%) |
| July 2008 | - | $40.10 K(-72.1%) |
| Apr 2008 | $143.70 K(+45.0%) | $143.70 K(+183.4%) |
| Jan 2008 | - | $50.70 K(-31.5%) |
| Oct 2007 | - | $74.00 K(+8.0%) |
| July 2007 | - | $68.50 K(-30.9%) |
| Apr 2007 | $99.10 K(+30.2%) | $99.10 K(-87.5%) |
| Jan 2007 | - | $794.70 K(+634.5%) |
| Oct 2006 | - | $108.20 K(+42.2%) |
| July 2006 | - | $76.10 K(0.0%) |
| Apr 2006 | $76.10 K(-70.5%) | $76.10 K(-68.0%) |
| Jan 2006 | - | $237.80 K(0.0%) |
| Oct 2005 | - | $237.80 K(+5.8%) |
| July 2005 | - | $224.70 K(-12.8%) |
| Apr 2005 | $257.80 K(>+9900.0%) | $257.80 K(+2309.3%) |
| Oct 2004 | - | $10.70 K(+109.8%) |
| July 2004 | - | $5100.00(+1600.0%) |
| Apr 2004 | $300.00(-88.0%) | $300.00(-94.2%) |
| Jan 2004 | - | $5200.00(+108.0%) |
| Apr 2003 | $2500.00 | $2500.00 |
FAQ
- What is PharmaCyte Biotech annual accounts payable?
- What is the all time high annual accounts payable for PharmaCyte Biotech?
- What is PharmaCyte Biotech annual accounts payable year-on-year change?
- What is PharmaCyte Biotech quarterly accounts payable?
- What is the all time high quarterly accounts payable for PharmaCyte Biotech?
- What is PharmaCyte Biotech quarterly accounts payable year-on-year change?
What is PharmaCyte Biotech annual accounts payable?
The current annual accounts payable of PMCB is $389.40 K
What is the all time high annual accounts payable for PharmaCyte Biotech?
PharmaCyte Biotech all-time high annual accounts payable is $730.10 K
What is PharmaCyte Biotech annual accounts payable year-on-year change?
Over the past year, PMCB annual accounts payable has changed by +$261.10 K (+203.51%)
What is PharmaCyte Biotech quarterly accounts payable?
The current quarterly accounts payable of PMCB is $554.00 K
What is the all time high quarterly accounts payable for PharmaCyte Biotech?
PharmaCyte Biotech all-time high quarterly accounts payable is $861.30 K
What is PharmaCyte Biotech quarterly accounts payable year-on-year change?
Over the past year, PMCB quarterly accounts payable has changed by +$427.80 K (+338.99%)